Malignant otitis externa
externarl malignant otithis
Summary
Malignant external otitis (MEO), also known as necrotizing otitis externa or skull base osteomyelitis, is a severe, invasive infection originating in the external auditory canal, primarily affecting elderly diabetic or immunocompromised patients, with Pseudomonas aeruginosa as the most common pathogen. It leads to osteomyelitis of the temporal bone and skull base, with high morbidity from cranial nerve palsies and potential mortality despite prolonged antibiotics; gallium scintigraphy aids in assessing treatment response and cure.[1][2][3][4][5]
Epidemiology and Prevalence
MEO predominantly occurs in older adults, with mean ages of 64-69 years across studies, showing male predominance (sex ratio ~1.5:1).[1][3][6] Diabetes mellitus is the key risk factor, present in 90-96% of cases, often with poor glycemic control; other factors include immunosuppression (e.g., leukemia) and rarely younger patients with conditions like Erdheim-Chester disease.[1][3][4][7] Prevalence is low but increasing recognition in diabetics; one series reported 50 cases over 11 years in a tertiary center, with 12% recurrence and 4% mortality after 10-month follow-up.[3] Fungal MEO (e.g., Aspergillus, Candida orthopsilosis) is rarer, mainly in immunocompromised hosts.[8][9][10]
Pathophysiology and Risk Factors
MEO begins as external otitis externa but invades soft tissues, bone, and skull base due to impaired immunity, particularly in diabetes where hyperglycemia impairs neutrophil function.[4][5][6] Pseudomonas aeruginosa is isolated in ~50-80% of culture-positive cases; emerging pathogens include Staphylococcus aureus and fungi.[3][11][12] Risk factors interact synergistically: diabetes increases susceptibility (p=0.03 for complications), with older age and severity correlating to worse outcomes.[6][12] Genetic/environmental factors are less defined, but poor glycemic control and diagnostic delay (>47 days average) worsen prognosis.[1][13]
Clinical Presentation and Health Impact
Core symptoms are severe otalgia (96%), otorrhea (80%), and hearing loss (32%), with granulation tissue (80%), facial palsy (54%), and multiple cranial neuropathies (e.g., VII, IX-XII) in advanced cases.[1][3][14] Complications include skull base osteomyelitis (100% hyperfixation on Tc99m scintigraphy), pseudoaneurysm, stroke, intracranial abscess, and death (2-4% in series).[15][3][16] Long-term sequelae: persistent cranial palsies, recurrence (12%), with facial nerve involvement (House-Brackmann ≥3) predicting poorer recovery (85% overall, but only 40% full/partial post-decompression).[17][18][19] Mortality remains significant despite antibiotics, linked to extensive disease.[12][20]
Diagnosis
Diagnosis relies on clinical triad (otalgia, otorrhea, granulation), risk factors, and imaging; biopsy rules out malignancy (e.g., squamous cell carcinoma).[21][22] Key diagnostics:
- Microbiology: Ear swab cultures (P. aeruginosa in 28-80%); fungal mNGS for culture-negative cases.[3][8]
- Labs: ESR/CRP elevated but nonspecific; normal WBC/CRP does not exclude.[2][23]
- Imaging:
Modality Findings Utility CT Soft tissue/bone erosion (40-73%) Initial extent[1][3] MRI Soft tissue/SBO involvement Complications[21][10] Tc99m-MDP bone scan Bone hyperfixation (100%) Early osteomyelitis[1][24] Ga67 scintigraphy Inflammation; resolution indicates cure Follow-up (e.g., after 6-12 weeks)[2][25]
Physiologically implausible vitals absent in query; request specifics if provided.
Treatment and Clinical Decision-Making
Primary: Prolonged antipseudomonal antibiotics (e.g., IV ciprofloxacin/ceftriaxone 4-6 weeks, then oral 3-12 months total), with glycemic control.[3][5][14] Escalate for nonresponse (e.g., cefepime to levofloxacin post-Ga67).[2] Hyperbaric oxygen adjunctive in refractory cases.[16][26]
- Surgery: Debridement/biopsy (74% cases), tympanomastoidectomy (76%), facial decompression (partial recovery 40%, not routine).[17][19][27] Indicated for refractory pain, abscess, or biopsy.
- Decision algorithm: Start empiric IV antibiotics + imaging; Ga67 for cure (negative after 74 days average).[1][2] Monitor ESR normalization; duration guided by scintigraphy, not symptoms alone.[3][26]
Guidelines: ENT-led, multidisciplinary (endocrinology, infectious disease); recent reviews emphasize early biopsy and fungal workup.[4][9]
Patient Safety and Variability
Contraindications/Side effects: Fluoroquinolones (tendon rupture, QT prolongation); monitor renal function, resistance.[3][12] Fungal: Voriconazole (hepatotoxicity, QT).[8] Surgical risks: Cranial nerve worsening (rare).[17]
Monitoring: Weekly clinical/labs, serial Ga67 (6 weeks-1 year), MRI for complications.[2][25] Risks managed via cultures, de-escalation.
Variability: Diabetics respond slower (p<0.05 complications); fungal worse prognosis; Peleg staging predicts outcome; non-Pseudomonas similar mortality but less diabetes.[6][12][26] Genetic/population differences understudied; higher recurrence in delayed diagnosis.[13]
Sources
- http://www.ajol.info/index.php/jtdorl/article/view/64239
- https://journals.sagepub.com/doi/10.1177/2050313X241253462
- https://www.ijorl.com/index.php/ijorl/article/view/4153
- https://link.springer.com/10.1007/s13300-023-01390-9
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10064349/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11863464/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8760005/
- https://www.frontiersin.org/articles/10.3389/fcimb.2023.1236414/full
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11555462/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8164024/
- http://www.scirp.org/journal/PaperDownload.aspx?paperID=50352
- https://academicjournals.org/journal/IJMMS/article-full-text-pdf/B9FAA0D64801.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5545692/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9444529/
- https://linkinghub.elsevier.com/retrieve/pii/S2542451321000560
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6346865/
- https://www.advancedotology.org/index.php/pub/article/view/1721
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10676830/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11645471/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6728081/
- https://actamedica.lfhk.cuni.cz/media/pdf/am_2021064010036.pdf
- https://juniperpublishers.com/gjo/GJO.MS.ID.555773.php
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6570638/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10693375/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11100390/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8020189/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6224839/
- https://www.semanticscholar.org/paper/6e296932849391b490ce87ab54800c228d94b206
- https://www.semanticscholar.org/paper/4979cc56082e942a9d30f6610151b5769d56b35d
- http://link.springer.com/10.1007/978-3-319-27987-9_34
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10290759/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9895558/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7458700/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7224427/
- https://www.cureus.com/articles/157822-clinical-spectrum-and-treatment-response-of-malignant-otitis-externa-patients-a-rural-tertiary-care-centre-experience
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7494786/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3649245/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5372270/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6424386/
- http://biomedpharmajournal.org/vol9no1/malignant-otitis-externa-in-south-west-of-iranan-epidemiological-investigation/
- https://journals.jsava.aosis.co.za/index.php/jsava/article/view/581
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6123115/
- https://assets.cureus.com/uploads/case_report/pdf/203847/20231201-17373-1snubkg.pdf
- https://linkinghub.elsevier.com/retrieve/pii/S180886941531137X
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3094778/
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ccr3.5276
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8710300/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3981260/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10762567/
- https://www.spandidos-publications.com/ol/5/5/1587/download
AI-generated answer based on the cited sources. Check the sources before applying it.